CA3155900A1 - Novel dosage forms of rofecoxib and related methods - Google Patents

Novel dosage forms of rofecoxib and related methods Download PDF

Info

Publication number
CA3155900A1
CA3155900A1 CA3155900A CA3155900A CA3155900A1 CA 3155900 A1 CA3155900 A1 CA 3155900A1 CA 3155900 A CA3155900 A CA 3155900A CA 3155900 A CA3155900 A CA 3155900A CA 3155900 A1 CA3155900 A1 CA 3155900A1
Authority
CA
Canada
Prior art keywords
formulation
rofecoxib
mean
achieves
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155900A
Other languages
English (en)
French (fr)
Inventor
Travis E. HELM
Bradford C. SIPPY
Raymond D. Skwierczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tremeau Pharmaceuticals Inc
Original Assignee
Helm Travis E
Sippy Bradford C
Tremeau Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helm Travis E, Sippy Bradford C, Tremeau Pharmaceuticals Inc filed Critical Helm Travis E
Publication of CA3155900A1 publication Critical patent/CA3155900A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3155900A 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods Pending CA3155900A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US62/934,898 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US63/018,136 2020-04-30
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
US16/867,514 2020-05-05
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (1)

Publication Number Publication Date
CA3155900A1 true CA3155900A1 (en) 2021-05-20

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155900A Pending CA3155900A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Country Status (9)

Country Link
US (5) US10945992B1 (enExample)
EP (1) EP4058012A1 (enExample)
JP (1) JP2023502941A (enExample)
KR (1) KR20220123224A (enExample)
CN (1) CN115605197A (enExample)
CA (1) CA3155900A1 (enExample)
MX (1) MX2022005813A (enExample)
TW (1) TW202128144A (enExample)
WO (1) WO2021097038A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US20200323813A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21647A (en) 1858-10-05 Construction of animal-traps
US21042A (en) 1858-07-27 yerby
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
CA2180651A1 (en) 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5849943A (en) 1994-10-27 1998-12-15 Merck Frosst Canada, Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
BR9709097A (pt) 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1646381A4 (en) * 2003-07-02 2009-12-09 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
AU2003263582A1 (en) 2003-08-14 2005-03-07 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
TR200301552A1 (tr) 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
WO2015066302A2 (en) * 2013-10-30 2015-05-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2016089893A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis
JP7291220B2 (ja) * 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用

Also Published As

Publication number Publication date
US20220409575A1 (en) 2022-12-29
MX2022005813A (es) 2022-08-16
JP2023502941A (ja) 2023-01-26
EP4058012A1 (en) 2022-09-21
WO2021097038A1 (en) 2021-05-20
TW202128144A (zh) 2021-08-01
US20210137878A1 (en) 2021-05-13
US10945992B1 (en) 2021-03-16
KR20220123224A (ko) 2022-09-06
US20210169845A1 (en) 2021-06-10
CN115605197A (zh) 2023-01-13
US20220047542A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
US20220409575A1 (en) Dosage forms of rofecoxib and related methods
AU764742B2 (en) Dispersible compositions containing L-DOPA ethyl ester
JP5344620B2 (ja) オルメサルタンメドキソミル及びアムロジピンの固形製剤
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
CA3038989A1 (en) Amlodipine formulations
US20070053975A1 (en) Ramipril formulation
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
JP3150642B2 (ja) 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
US8309607B2 (en) Rapid release irbesartan-containing pharmaceutical composition
US20250319070A1 (en) Losartan liquid formulations and methods of use
ADVIL et al. CHILDREN’S ADVIL® CHEWABLE TABLETS
EP4585207A1 (en) Synergic and stable pharmaceutical composition of an nsaid and an opioid analgesic for pain and inflammation
CN115666564B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
ULC Aldosterone Antagonist
WO2026067737A1 (zh) 三唑类化合物的药物制剂及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107